Barbara-Jean Bormann-Kennedy Sells 15,000 Shares of Xeris Biopharma (NASDAQ:XERS) Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Director Barbara-Jean Bormann-Kennedy sold 15,000 shares of Xeris Biopharma stock in a transaction on Friday, December 12th. The shares were sold at an average price of $7.09, for a total value of $106,350.00. Following the completion of the transaction, the director owned 142,500 shares in the company, valued at approximately $1,010,325. The trade was a 9.52% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Xeris Biopharma Stock Up 0.7%

NASDAQ:XERS opened at $7.10 on Wednesday. Xeris Biopharma Holdings, Inc. has a twelve month low of $3.14 and a twelve month high of $10.08. The stock’s 50-day simple moving average is $7.94 and its 200 day simple moving average is $6.84. The firm has a market capitalization of $1.18 billion, a PE ratio of -70.99 and a beta of 0.57.

Xeris Biopharma (NASDAQ:XERS) last posted its earnings results on Thursday, November 6th. The company reported $0.00 EPS for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.01). The firm had revenue of $74.38 million for the quarter, compared to analysts’ expectations of $74.19 million. On average, analysts anticipate that Xeris Biopharma Holdings, Inc. will post -0.41 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Xeris Biopharma in a research note on Friday, November 7th. Piper Sandler raised their price objective on Xeris Biopharma from $6.00 to $8.00 and gave the company a “neutral” rating in a report on Friday, November 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Xeris Biopharma in a research report on Wednesday, October 8th. Wall Street Zen downgraded Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Saturday, November 8th. Finally, Leerink Partners lifted their price target on Xeris Biopharma from $7.00 to $9.00 and gave the company an “outperform” rating in a research note on Tuesday, August 19th. Six analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $9.50.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Cetera Investment Advisers acquired a new position in Xeris Biopharma during the 1st quarter worth about $245,000. Vanguard Group Inc. raised its position in shares of Xeris Biopharma by 2.7% during the first quarter. Vanguard Group Inc. now owns 8,109,644 shares of the company’s stock worth $44,522,000 after acquiring an additional 210,581 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Xeris Biopharma by 5.2% in the first quarter. Charles Schwab Investment Management Inc. now owns 423,775 shares of the company’s stock worth $2,327,000 after acquiring an additional 20,903 shares during the period. Deutsche Bank AG boosted its holdings in Xeris Biopharma by 492.8% in the first quarter. Deutsche Bank AG now owns 756,407 shares of the company’s stock valued at $4,153,000 after acquiring an additional 628,807 shares during the last quarter. Finally, Invesco Ltd. increased its position in Xeris Biopharma by 1,387.8% during the 1st quarter. Invesco Ltd. now owns 1,026,838 shares of the company’s stock valued at $5,637,000 after purchasing an additional 957,822 shares during the period. 42.75% of the stock is owned by institutional investors.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.